Every 10-Q that LENSAR, Inc. (LNSR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LNSR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LNSR filings page.
LENSAR, Inc. reported higher revenue and a sharp swing to profitability for the quarter ended June 30, 2026. Total revenue rose to $16.5M from $13.9M a year earlier, driven primarily by higher procedure volumes across its LENSAR Laser System and ALLY Robotic Cataract Laser System platforms.
Operating results improved significantly, with operating income of $2.1M versus a loss of $6.3M in the prior-year quarter, reflecting lower selling, general and administrative expenses and the absence of prior acquisition-related costs. Net income was $3.5M, compared with a net loss of $1.8M, aided by a favorable change in warrant liabilities. For the first six months, net income reached $39.9M, largely influenced by a $10.0M cash deposit retained from the terminated Alcon merger and a $25.2M non-cash gain from revaluing warrant liabilities.
Cash and cash equivalents were $13.6M at June 30, 2026, slightly above year-end despite $4.4M of cash used in operating activities, helped by investment maturities. Warrant liabilities fell from $40.2M to $15.0M, and stockholders’ equity moved from a deficit of $26.0M to positive $14.9M. Management still expects near-term operating losses but believes existing liquidity and an additional $10.0M asset-based revolving credit facility executed in August 2026 support at least 12 months of funding.
LENSAR, Inc. reported quarterly revenue of $13.4 million, down slightly from $14.2 million a year earlier as system sales declined while procedure, lease and service revenue kept recurring revenue at 94% of the total. The company swung to net income of $36.3 million from a $27.3 million loss, driven mainly by a $23.9 million favorable change in warrant liabilities and $10.0 million of acquisition-related income from retaining the terminated Alcon merger deposit, plus a reduction of previously accrued deal costs. Core operations still used $4.3 million of operating cash, leaving $12.5 million in cash and $1.0 million in short-term investments as of March 31, 2026. Management continues to invest in commercialization of its ALLY Robotic Cataract Laser System, notes ongoing macroeconomic and tariff pressures on component costs, and believes current liquidity and expected sales are sufficient for at least the next 12 months.
LENSAR, Inc. reported Q3 2025 results and provided updates on its pending merger with Alcon. Revenue was $14.3 million (up from $13.5 million), driven by product sales of $11.4 million, lease revenue of $1.6 million, and service revenue of $1.4 million. Operating loss widened to $7.6 million, and net loss was $3.7 million versus $1.5 million a year ago, reflecting higher selling, general and administrative expenses, including $5.3 million in acquisition-related costs this quarter.
Year to date, revenue reached $42.4 million (from $36.8 million) with a net loss of $32.8 million. Cash and cash equivalents were $7.6 million with $9.2 million in short-term investments. Warrant liabilities rose to $43.5 million, contributing a $(13.6) million year-to-date non-cash charge.
Under the Merger Agreement, each share will be converted into $14.00 in cash plus a contingent value right of $2.75 upon achieving 614,000 cumulative procedures between January 1, 2026 and December 31, 2027. The company received a $10.0 million acquisition-related deposit, recorded as a current liability. As of October 24, 2025, common shares outstanding were 11,944,546.